A Science & Innovation Webinar, sponsored by GSK.

Lupus is a disease of progressive, and often irreversible, organ damage. It is more common in women and non-white populations. Factors such as long-term use of corticosteroids, high disease activity and flares may increase the risk of organ damage, while lupus nephritis may lead to significant chronic kidney disease, and potentially end stage kidney disease. Recently updated EULAR and KDIGO guidelines reflect up-to-date evidence and expert consensus and may be applied to your populations to improve patient outcomes, including minimizing toxicities, flares and risk of organ damage progression.

Neovascular, or wet, age-related macular degeneration (wet AMD) is a significant cause of central visual impairment, contributing to about half of all cases of blindness in Americans aged 50 years and older. The estimated number of individuals affected by wet AMD in the United States is projected to double to 5.4 million between 2010 and 2050. Although there is currently no cure for wet AMD, there are treatment options that slow disease progression.

In this webinar, key panelists will share insights curated from AMCP's Market Insights program on the patient burden of wet AMD and how payers can best manage it by considering factors such as timeliness of treatment, treatment durability, and cost-effective treatment strategies.

A Science & Innovation Webinar, sponsored by Abbvie.

Ulcerative colitis is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The STRIDE II Recommendations for moderate to severe ulcerative colitis include long-term goals for the management of the disease.

There is a need for new treatment options, with a focus on long-term patient outcomes. An IL-23 inhibitor was recently approved for the treatment of moderate to severe ulcerative colitis. The objective of this webinar is to review the ulcerative colitis disease state, treatment guidelines, and the pivotal trials program for this recently approved indication for an IL-23 inhibitor.

A Science & Innovation Webinar, sponsored by Impact Education, LLC.

Retinal diseases result in remarkable morbidity among plan members, including vision loss and blindness. Furthermore, disparities exist in incidence and outcomes among those affected by social determinants of health (SDOH). This webcast, presented by ManagedCareEye.com, will educate managed care and payer professionals regarding best practices in enhancing retinal disease care equity and access.

Learning Objectives

• Identify current disparities in the care of retinal diseases.
• Outline the importance of anti-VEGF therapies with extended duration of effect for patients impacted by SDOH.
• Describe means by which to address the impact of SDOH via utilization management programs.

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Syndax Pharmaceuticals.

Pre-Approval Information Exchange (PIE) presentation for investigational revumenib, including a clinical overview, burden of disease, and disease background for pediatric and adult patients harboring KMT2A-rearranged relapsed or refractory acute leukemia.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

The AMCP Format for Formulary Submissions (the Format) defines the best practice for pharmaceutical manufacturer dossiers. In April 2024, AMCP released Format version 5.0, the first update to the Format since 2020. In this educational session, two individuals who contributed to the update will provide details of the new and improved Format v5.0.

An AMCP Webinar, hosted by FormularyDecisions^®.

Please join us for an interactive, engaging, and informative discussion to discover the keys to thriving in the dynamic biosimilars landscape. In this interactive session, you will gain practical insights on navigating regulatory challenges, seizing opportunities for collaboration, and communicating effectively with stakeholders.

Stay ahead of the curve with up-to-date industry trends and expert strategies tailored to driving success in the U.S. biosimilars market. Register today to secure your spot!

Open to AMCP Members Only

This webinar will provide an overview for AMCP Members considering future Board Service. Join this session to learn the information you need to prepare, including Board responsibilities, expectations, AMCP's commitment to diversity and inclusion, the Leadership Development committee selection process, and information on AMCP's Entities: AMCP Foundation, AMCP Research Institute and BBCIC, Committees, and AMCP's Strategic and Policy Priorities.

An AMCP CPE Webinar.

Breast cancer stands as one of the leading forms of cancer nationwide, affecting thousands of people every year. Behind this statistic lie complex health disparities that significantly influence treatment outcomes, particularly among marginalized groups.

This session will explore the latest advancements in breast cancer management and analyze the intersection of gender and health disparities that contribute to health outcomes. Additionally, it will explore different managed care strategies to improve equitable access to treatment for vulnerable populations.

This activity is supported by an independent medical education grant from Merck and Novartis.